Deferiprone
| 證據等級: L5 | 預測適應症: 9 個 |
目錄
Deferiprone: From Transfusional Iron Overload to Hepatic Porphyria
One-Sentence Summary
Deferiprone is an oral iron chelator approved by the FDA (2011) for transfusional iron overload in thalassemia patients, though it is not currently registered in Saudi Arabia. The TxGNN model predicts it may be effective for Hepatic Porphyria, with 0 clinical trials and 2 publications currently supporting this direction. The mechanistic rationale is scientifically coherent — hepatic iron accumulation is a key driver of porphyrin toxicity — but formal clinical validation is absent.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Transfusional iron overload (thalassemia) — FDA-approved 2011; not registered in Saudi Arabia |
| Predicted New Indication | Hepatic Porphyria |
| TxGNN Prediction Score | 99.20% |
| Evidence Level | L4 |
| Saudi Arabia Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack. Based on known information, deferiprone is an orally active bidentate hydroxypyridinone iron chelator that binds ferric iron (Fe³⁺) with high affinity and promotes its excretion via urine and feces. A key property distinguishing it from other chelators is its ability to cross cell membranes, enabling removal of intracellular iron stores — including from hepatocytes and erythroid precursors.
Hepatic porphyrias — including porphyria cutanea tarda (PCT) and congenital erythropoietic porphyria (CEP) — share a critical pathophysiological feature: excess free iron in the liver catalyzes oxidative conversion of porphyrinogens to toxic porphyrin isomers, driving both skin photosensitivity and hemolytic anemia. Iron removal by phlebotomy is already standard care for PCT precisely because reducing hepatic iron content is therapeutic. Deferiprone, as an oral chelator, offers the same depletion mechanism in patients who cannot tolerate phlebotomy.
Two supporting publications reinforce this rationale. Blouin et al. (Blood, 2020) demonstrated in a clinical case series that oral iron chelation rescued hemolytic anemia and skin photosensitivity in CEP patients, directly validating the therapeutic concept. Gorman et al. (Hepatology, 2007) confirmed in an Hfe⁻/⁻ murine PCT model that deferiprone reduced hepatic uroporphyrin accumulation to a degree comparable to iron-deficient diets. The mechanistic link is clear; the gap is the absence of prospective clinical trials.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32678895 | 2020 | Clinical Case Study | Blood | Oral iron chelation rescued hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria (CEP); reduction in pathological uroporphyrin isomer I accumulation demonstrated in patients with UROS deficiency |
| 17854053 | 2007 | Animal Model | Hepatology | Deferiprone (L1) significantly reduced hepatic uroporphyrin accumulation in Hfe⁻/⁻ mice with ALA-induced PCT; effect was comparable to iron-deficient diet, supporting iron chelation as a mechanistic surrogate for phlebotomy |
Saudi Arabia Market Information
Deferiprone is not currently registered in Saudi Arabia and holds no active product authorizations. For reference, the drug is approved by the FDA (since 2011) and EMA for transfusional iron overload in thalassemia major patients. No locally approved products are on record.
Safety Considerations
Please refer to the package insert for safety information.
Note for reviewers: Although in-scope safety data was not available in this evidence pack, global regulatory labels carry a Black Box Warning for agranulocytosis and neutropenia requiring weekly absolute neutrophil count (ANC) monitoring. This is a critical safety consideration for any clinical development plan and should be formally reviewed before advancing this candidate.
Conclusion and Next Steps
Decision: Research Question
Rationale: The mechanistic link between iron chelation and hepatic porphyria is scientifically sound and supported by analogous clinical practice (phlebotomy in PCT), but current evidence is limited to one case series and one murine model (Evidence Level L4), with no registered clinical trials. This is a hypothesis worth pursuing — not a candidate ready for formulary evaluation.
To proceed, the following is needed:
- Systematic literature review covering iron chelation in PCT, CEP, and related hepatic porphyrias to identify additional preclinical or observational evidence not captured in this evidence pack
- Review of full package insert warnings and contraindications (particularly agranulocytosis risk) before any clinical protocol is drafted
- Retrieval of deferiprone MOA from DrugBank to complete mechanistic scoring
- Assessment of whether a pilot investigator-initiated trial (IIT) is feasible in CEP or PCT patients with documented iron overload in the target market
- Market access feasibility analysis for Saudi Arabia registration given zero current approvals in the region
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.